{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T23:52:31Z","timestamp":1788306751886,"version":"build-2803163510"},"reference-count":73,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T00:00:00Z","timestamp":1754524800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T00:00:00Z","timestamp":1754524800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"DOI":"10.1186\/s12876-025-04154-w","type":"journal-article","created":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T04:06:34Z","timestamp":1754539594000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Safety of infliximab and adalimumab in pediatric inflammatory bowel diseases: a disproportionality analysis from the FAERS database"],"prefix":"10.1186","volume":"25","author":[{"given":"Yanhong","family":"Deng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengying","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Senling","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangping","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinling","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinjin","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaozhi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanmei","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,7]]},"reference":[{"issue":"4","key":"4154_CR1","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1053\/j.gastro.2021.12.282","volume":"162","author":"ME Kuenzig","year":"2022","unstructured":"Kuenzig ME, Fung SG, Marderfeld L, Mak JWY, Kaplan GG, Ng SC, et al. Twenty-first century trends in the global epidemiology of pediatric-onset inflammatory bowel disease: systematic review. Gastroenterology. 2022;162(4):1147\u201359. e4.","journal-title":"Gastroenterology"},{"issue":"6","key":"4154_CR2","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1002\/ibd.21152","volume":"16","author":"B Pigneur","year":"2010","unstructured":"Pigneur B, Seksik P, Viola S, Viala J, Beaugerie L, Girardet JP, et al. Natural history of crohn\u2019s disease: comparison between childhood- and adult-onset disease. Inflamm Bowel Dis. 2010;16(6):953\u201361.","journal-title":"Inflamm Bowel Dis"},{"issue":"6","key":"4154_CR3","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.3748\/wjg.v23.i6.1067","volume":"23","author":"G Chouliaras","year":"2017","unstructured":"Chouliaras G, Margoni D, Dimakou K, Fessatou S, Panayiotou I, Roma-Giannikou E. Disease impact on the quality of life of children with inflammatory bowel disease. World J Gastroenterol. 2017;23(6):1067\u201375.","journal-title":"World J Gastroenterol"},{"issue":"4","key":"4154_CR4","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.dld.2018.11.033","volume":"51","author":"M Fumery","year":"2019","unstructured":"Fumery M, Pariente B, Sarter H, Savoye G, Spyckerelle C, Djeddi D, et al. Long-term outcome of pediatric-onset Crohn\u2019s disease: a population-based cohort study. Dig Liver Dis. 2019;51(4):496\u2013502.","journal-title":"Dig Liver Dis"},{"issue":"10","key":"4154_CR5","doi-asserted-by":"publisher","first-page":"2529","DOI":"10.3390\/ijms20102529","volume":"20","author":"MA Aardoom","year":"2019","unstructured":"Aardoom MA, Veereman G, de Ridder L. A review on the use of anti-TNF in children and adolescents with inflammatory bowel disease. Int J Mol Sci. 2019;20(10):2529.","journal-title":"Int J Mol Sci"},{"issue":"2","key":"4154_CR6","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s40272-017-0267-8","volume":"20","author":"S Pastore","year":"2018","unstructured":"Pastore S, Naviglio S, Canuto A, Lepore L, Martelossi S, Ventura A, et al. Serious adverse events associated with anti-tumor necrosis factor alpha agents in pediatric-onset inflammatory bowel disease and juvenile idiopathic arthritis in a real-life setting. Paediatr Drugs. 2018;20(2):165\u201371.","journal-title":"Paediatr Drugs"},{"issue":"9","key":"4154_CR7","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1093\/ibd\/izad196","volume":"30","author":"LV Collen","year":"2024","unstructured":"Collen LV, Mitsialis V, Kim DY, et al. Efficacy and safety of anti-tumor necrosis factor alpha in very early onset inflammatory bowel disease. Inflamm Bowel Di. 2024;30(9):1443\u201353.","journal-title":"Inflamm Bowel Di"},{"issue":"5","key":"4154_CR8","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1093\/rheumatology\/keg263","volume":"42","author":"S Kroesen","year":"2023","unstructured":"Kroesen S, Widmer AF, Tyndall A, Hasler P. Serious bacterial infections in patients with rheumatoid arthritis under anti-TNF-alpha therapy. Rheumatology (Oxford). 2023;42(5):617\u201321.","journal-title":"Rheumatology (Oxford)"},{"issue":"12","key":"4154_CR9","doi-asserted-by":"publisher","first-page":"2862","DOI":"10.1002\/1529-0131(200112)44:12<2862::AID-ART474>3.0.CO;2-W","volume":"44","author":"N Mohan","year":"2001","unstructured":"Mohan N, Edwards ET, Cupps TR, Oliverio PJ, Sandberg G, Crayton H, et al. Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum. 2001;44(12):2862\u20139.","journal-title":"Arthritis Rheum"},{"issue":"6","key":"4154_CR10","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1111\/apt.15097","volume":"49","author":"UN Shivaji","year":"2019","unstructured":"Shivaji UN, Sharratt CL, Thomas T, Smith SCL, Iacucci M, Moran GW, et al. Review article: managing the adverse events caused by anti-TNF therapy in inflammatory bowel disease. Aliment Pharmacol Ther. 2019;49(6):664\u201380.","journal-title":"Aliment Pharmacol Ther"},{"issue":"3","key":"4154_CR11","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.autrev.2009.10.003","volume":"9","author":"M Ramos-Casals","year":"2010","unstructured":"Ramos-Casals M, Roberto-Perez-Alvarez, Diaz-Lagares C, Cuadrado MJ, Khamashta MA. Autoimmune diseases induced by biological agents: a double-edged sword. Autoimmun Rev. 2010;9(3):188\u201393.","journal-title":"Autoimmun Rev"},{"issue":"1","key":"4154_CR12","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1097\/MPG.0000000000001188","volume":"63","author":"MI Ardura","year":"2016","unstructured":"Ardura MI, Toussi SS, Siegel JD, Lu Y, Bousvaros A, Crandall W. NASPGHAN clinical report: surveillance, diagnosis, and prevention of infectious diseases in pediatric patients with inflammatory bowel disease receiving tumor necrosis factor-\u03b1 inhibitors. J Pediatr Gastroenterol Nutr. 2016;63(1):130\u201355.","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"10","key":"4154_CR13","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1080\/17474124.2019.1663173","volume":"13","author":"P Alvisi","year":"2019","unstructured":"Alvisi P, Dipasquale V, Barabino A, Martellossi S, Miele E, Lionetti P, et al. Infections and malignancies risks related to TNF-\u03b1-blocking agents in pediatric inflammatory bowel diseases. Expert Rev Gastroenterol Hepatol. 2019;13(10):957\u201361.","journal-title":"Expert Rev Gastroenterol Hepatol"},{"issue":"3","key":"4154_CR14","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1093\/ced\/llae432","volume":"50","author":"D Hilewitz","year":"2025","unstructured":"Hilewitz D, Yacobovitz S, Reiss-Huss S, Matar M, Weintraub Y, Shouval DS, et al. Paradoxical psoriasiform skin eruption in paediatric patients with inflammatory bowel disease treated with tumour necrosis factor-\u03b1 inhibitors. Clin Exp Dermatol. 2025;50(3):558\u201363.","journal-title":"Clin Exp Dermatol"},{"issue":"4","key":"4154_CR15","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1177\/1203475420917387","volume":"24","author":"ML Cossio","year":"2020","unstructured":"Cossio ML, Genois A, Jantchou P, Hatami A, Deslandres C, McCuaig C. Skin manifestations in pediatric patients treated with a TNF-alpha inhibitor for inflammatory bowel disease: a retrospective study. J Cutan Med Surg. 2020;24(4):333\u20139.","journal-title":"J Cutan Med Surg"},{"issue":"2","key":"4154_CR16","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/s40272-021-00440-8","volume":"23","author":"N Rosenwasser","year":"2021","unstructured":"Rosenwasser N, Lee D, Sidbury R, Zhao Y. Paradoxical psoriasis in children receiving anti-TNF \u03b1 treatment foriinflammatory\/autoimmune disease. Paediatr Drugs. 2021;23(2):131\u201341.","journal-title":"Paediatr Drugs"},{"issue":"6","key":"4154_CR17","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1001\/jamadermatol.2023.0549","volume":"159","author":"J Eickstaedt","year":"2023","unstructured":"Eickstaedt J, Paller AS, Lund E, Murphrey M, Brandling-Bennett H, Maurano M, et al. Paradoxical psoriasiform eruptions in children receiving tumor necrosis factor \u03b1 inhibitors. JAMA Dermatol. 2023;159(6):637\u201342.","journal-title":"JAMA Dermatol"},{"issue":"8","key":"4154_CR18","doi-asserted-by":"publisher","first-page":"3207","DOI":"10.1007\/s00277-024-05691-2","volume":"103","author":"W Li","year":"2024","unstructured":"Li W, Fu Y, Wang W. A real-world pharmacovigilance study investigating the toxicities of histone deacetylase inhibitors. Ann Hematol. 2024;103(8):3207\u201317.","journal-title":"Ann Hematol"},{"key":"4154_CR19","doi-asserted-by":"publisher","unstructured":"Dong S, Guo X, Wang H, Sun C. Liver injury due to endothelin receptor antagonists: a real-world study based on post-marketing drug monitoring data. Ther Adv Respir Dis. 2024;18:17534666231223606. https:\/\/doi.org\/10.1177\/17534666231223606.","DOI":"10.1177\/17534666231223606"},{"issue":"6","key":"4154_CR20","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1002\/pds.1742","volume":"18","author":"A Bate","year":"2009","unstructured":"Bate A, Evans SJ. Quantitative signal detection using spontaneous ADR reporting. Pharmacoepidemiol Drug Saf. 2009;18(6):427\u201336.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"9","key":"4154_CR21","doi-asserted-by":"publisher","first-page":"2705","DOI":"10.1016\/j.ekir.2024.07.006","volume":"9","author":"J Wang","year":"2024","unstructured":"Wang J, Zhang Z, Liu X, Shi S, Lv J, Zhang Y, et al. Exploring novel adverse events of Nefecon. Kidney Int Rep. 2024;9(9):2705\u201317.","journal-title":"Kidney Int Rep"},{"issue":"7","key":"4154_CR22","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1080\/14740338.2024.2359615","volume":"23","author":"W Dou","year":"2024","unstructured":"Dou W, Liu X, An P, Zuo W, Zhang B. Real-world safety profile of tetracyclines in children younger than 8 years old: an analysis of FAERS database and review of case report. Expert Opin Drug Saf. 2024;23(7):885\u201392.","journal-title":"Expert Opin Drug Saf"},{"issue":"6","key":"4154_CR23","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1016\/j.jaad.2025.02.031","volume":"92","author":"A Joshi","year":"2025","unstructured":"Joshi A, Gawey L, Saadi C, Naidoo P, Rick JW, Park SY. Postmarketing safety surveillance of adalimumab, secukinumab, and infliximab in hidradenitis suppurativa: an analysis of the FDA adverse events reporting system (FAERS) database. J Am Acad Dermatol. 2025;92(6):1434\u20135.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"4154_CR24","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1097\/MPG.0000000000002035","volume":"67","author":"D Turner","year":"2018","unstructured":"Turner D, Ruemmele FM, Orlanski-Meyer E, Griffiths AM, de Carpi JM, Bronsky J, et al. Management of paediatric ulcerative colitis, part 1: ambulatory care-an evidence-based guideline from European crohn\u2019s and colitis organization and European society of paediatric gastroenterology, hepatology and nutrition. J Pediatr Gastroenterol Nutr. 2018;67(2):257\u201391.","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"7","key":"4154_CR25","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1038\/ajg.2017.97","volume":"112","author":"EI Benchimol","year":"2017","unstructured":"Benchimol EI, Bernstein CN, Bitton A, Carroll MW, Singh H, Otley AR, et al. Trends in epidemiology of pediatric inflammatory bowel disease in Canada: distributed network analysis of multiple population-based provincial health administrative databases. Am J Gastroenterol. 2017;112(7):1120\u201334.","journal-title":"Am J Gastroenterol"},{"key":"4154_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2023.106935","volume":"196","author":"F Penagini","year":"2023","unstructured":"Penagini F, Lonoce L, Abbattista L, Silvera V, Rendo G, Cococcioni L, et al. Dual biological therapy and small molecules in pediatric inflammatory bowel disease. Pharmacol Res. 2023;196: 106935.","journal-title":"Pharmacol Res"},{"issue":"18","key":"4154_CR27","doi-asserted-by":"publisher","first-page":"2784","DOI":"10.3748\/wjg.v29.i18.2784","volume":"29","author":"ES Kim","year":"2023","unstructured":"Kim ES, Kang B. Infliximab vs adalimumab: points to consider when selecting anti-tumor necrosis factor agents in pediatric patients with crohn\u2019s disease. World J Gastroenterol. 2023;29(18):2784\u201397.","journal-title":"World J Gastroenterol"},{"issue":"10","key":"4154_CR28","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1111\/apt.14030","volume":"45","author":"A Cholapranee","year":"2017","unstructured":"Cholapranee A, Hazlewood GS, Kaplan GG, Peyrin-Biroulet L, Ananthakrishnan AN. Systematic review with meta-analysis: comparative efficacy of biologics for induction and maintenance of mucosal healing in Crohn\u2019s disease and ulcerative colitis controlled trials. Aliment Pharmacol Ther. 2017;45(10):1291\u2013302.","journal-title":"Aliment Pharmacol Ther"},{"issue":"6","key":"4154_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2024.103586","volume":"23","author":"X Wang","year":"2024","unstructured":"Wang X, Xiu R, Gong L, Sun W, Dong Y, Liu W, et al. Unraveling the global burden of inflammatory bowel disease (1990\u20132019): a joinpoint regression analysis of divergent trends in 10\u201324 and 50\u201369 age cohorts. Autoimmun Rev. 2024;23(6): 103586.","journal-title":"Autoimmun Rev"},{"issue":"9","key":"4154_CR30","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1093\/ecco-jcc\/jjv096","volume":"9","author":"L Lichtenstein","year":"2015","unstructured":"Lichtenstein L, Ron Y, Kivity S, Ben-Horin S, Israeli E, Fraser GM, et al. Infliximab-related infusion reactions: systematic review. J Crohns Colitis. 2015;9(9):806\u201315.","journal-title":"J Crohns Colitis"},{"issue":"12","key":"4154_CR31","doi-asserted-by":"publisher","first-page":"2104","DOI":"10.1097\/MIB.0000000000001259","volume":"23","author":"W El-Matary","year":"2017","unstructured":"El-Matary W, Dykes DMH, Bauman L, Elkadri A, Carroll MW, Izaguirre MR, et al. Rapid Infliximab infusion in children with inflammatory bowel disease: a multicenter North American experience. Inflamm Bowel Dis. 2017;23(12):2104\u20138.","journal-title":"Inflamm Bowel Dis"},{"issue":"10","key":"4154_CR32","doi-asserted-by":"publisher","first-page":"1882","DOI":"10.1097\/MIB.0000000000001189","volume":"23","author":"SL Gold","year":"2017","unstructured":"Gold SL, Cohen-Mekelburg S, Schneider Y, Shen N, Faggen A, Rupert A, et al. Premedication use in preventing acute Infliximab infusion reactions in patients with inflammatory bowel disease: a single center cohort study. Inflamm Bowel Dis. 2017;23(10):1882\u20139.","journal-title":"Inflamm Bowel Dis"},{"issue":"14","key":"4154_CR33","doi-asserted-by":"publisher","first-page":"3177","DOI":"10.3390\/jcm10143177","volume":"10","author":"E Szymanska","year":"2021","unstructured":"Szymanska E, Dadalski M, Sieczkowska-Golub J, Jarzebicka D, Meglicka M, Osiecki M, et al. Premedication does not influence the incidence of Infliximab infusion reactions in pediatric patients with inflammatory bowel disease- a single center case-control study. J Clin Med. 2021;10(14):3177.","journal-title":"J Clin Med"},{"issue":"2","key":"4154_CR34","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1517\/14740338.2013.755957","volume":"12","author":"G Murdaca","year":"2013","unstructured":"Murdaca G, Span\u00f2 F, Puppo F. Selective TNF-alpha inhibitor-induced injection site reactions. Expert Opin Drug Saf. 2013;12(2):187\u201393.","journal-title":"Expert Opin Drug Saf"},{"issue":"2","key":"4154_CR35","doi-asserted-by":"publisher","first-page":"102","DOI":"10.7150\/ijms.17025","volume":"14","author":"E Szymanska","year":"2017","unstructured":"Szymanska E, Dadalski M, Sieczkowska-Golub J, Jarzebicka D, Meglicka M, Osiecki M, et al. Age-related trends in injection site reaction incidence induced by the tumor necrosis factor-\u03b1 (TNF-\u03b1) inhibitors etanercept and adalimumab: the food and drug administration adverse event reporting system. Int J Med Sci. 2017;14(2):102\u20139.","journal-title":"Int J Med Sci"},{"issue":"5","key":"4154_CR36","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1007\/s12325-024-02818-9","volume":"41","author":"JR Allegretti","year":"2024","unstructured":"Allegretti JR, Brady JH, Wicker A, Latymer M, Wells A. Relevance of adalimumab product attributes to patient experience in the biosimilar era: a narrative review. Adv Ther. 2024;41(5):1775\u201394.","journal-title":"Adv Ther"},{"issue":"6","key":"4154_CR37","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.crohns.2013.12.013","volume":"8","author":"JF Rahier","year":"2014","unstructured":"Rahier JF, Magro F, Abreu C, Armuzzi A, Ben-Horin S, Chowers Y, European crohn\u2019s and colitis organisation (ECCO), et al. Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis. 2014;8(6):443\u201368.","journal-title":"J Crohns Colitis"},{"issue":"2","key":"4154_CR38","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1053\/j.gastro.2018.04.012","volume":"155","author":"J Kirchgesner","year":"2018","unstructured":"Kirchgesner J, Lemaitre M, Carrat F, Zureik M, Carbonnel F, Dray-Spira R. Risk of serious and opportunistic infections associated with treatment of inflammatory bowel diseases. Gastroenterology. 2018;155(2):337-e34610.","journal-title":"Gastroenterology"},{"issue":"3","key":"4154_CR39","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1093\/ibd\/izac097","volume":"29","author":"J Holmgren","year":"2023","unstructured":"Holmgren J, Fr\u00f6borg A, Visuri I, Halfvarson J, Hjortswang H, Karling P, et al. The the risk of serious infections before and after anti-TNF therapy in inflammatory bowel disease: a retrospective cohort study. Inflamm Bowel Dis. 2023;29(3):339\u201348.","journal-title":"Inflamm Bowel Dis"},{"issue":"9","key":"4154_CR40","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1016\/j.cgh.2014.01.021","volume":"12","author":"PS Dulai","year":"2014","unstructured":"Dulai PS, Thompson KD, Blunt HB, Dubinsky MC, Siegel CA. A. Risks of serious infection or lymphoma with anti-tumor necrosis factor therapy for pediatric inflammatory bowel disease: a systematic review. Clin Gastroenterol Hepatol. 2014;12(9):1443\u201351.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"11","key":"4154_CR41","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/S2468-1253(19)30266-3","volume":"4","author":"V Wintzell","year":"2019","unstructured":"Wintzell V, Svanstr\u00f6m H, Melbye M, Jess T, Ol\u00e9n O, Ludvigsson JF, et al. Use of tumour necrosis factor-\u03b1 inhibitors and the risk of serious infection in paediatric inflammatory bowel disease in denmark: a nationwide cohort study. Lancet Gastroenterol Hepatol. 2019;4(11):845\u201353.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"4","key":"4154_CR42","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1136\/gut.2008.163642","volume":"58","author":"H Fidder","year":"2019","unstructured":"Fidder H, Schnitzler F, Ferrante M, Noman M, Katsanos K, Segaert S, et al. Long-term safety of Infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study. Gut. 2019;58(4):501\u20138.","journal-title":"Gut"},{"issue":"12","key":"4154_CR43","doi-asserted-by":"publisher","first-page":"1806","DOI":"10.1038\/ajg.2016.433","volume":"111","author":"MT Osterman","year":"2016","unstructured":"Osterman MT, Sandborn WJ, Colombel JF, Peyrin-Biroulet L, Robinson AM, Zhou Q, et al. Crohn\u2019s disease activity and concomitant immunosuppressants affect the risk of serious and opportunistic infections in patients treated with adalimumab. Am J Gastroenterol. 2016;111(12):1806\u201315.","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"4154_CR44","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1093\/ibd\/izx089","volume":"24","author":"NH Nguyen","year":"2018","unstructured":"Nguyen NH, Ohno-Machado L, Sandborn WJ, Singh S. Infections and cardiovascular complications are common causes for hospitalization in older patients with inflammatory bowel diseases. Inflamm Bowel Dis. 2018;24(4):916\u201323.","journal-title":"Inflamm Bowel Dis"},{"issue":"4","key":"4154_CR45","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/j.cgh.2023.10.013","volume":"22","author":"K M\u00e5rild","year":"2024","unstructured":"M\u00e5rild K, S\u00f6derling J, Axelrad J, Halfvarson J, Forss A, SWIBREG Study Group. Histologic activity in inflammatory bowel disease and risk of serious infections: a nationwide study. Clin Gastroenterol Hepatol. 2024;22(4):831\u201346.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"4154_CR46","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1093\/ibd\/izx080","volume":"24","author":"WJ Lee","year":"2018","unstructured":"Lee WJ, Lee TA, Calip GS, Suda KJ, Briars L, Schumock GT. Risk of serious bacterial infection associated with tumor necrosis factor-alpha inhibitors in children and young adults with inflammatory bowel disease. Inflamm Bowel Dis. 2018;24(4):883\u201391.","journal-title":"Inflamm Bowel Dis"},{"issue":"17","key":"4154_CR47","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1001\/jama.2017.16071","volume":"318","author":"M Lemaitre","year":"2017","unstructured":"Lemaitre M, Kirchgesner J, Rudnichi A, Carrat F, Zureik M, Carbonnel F, et al. Association between use of thiopurines or tumor necrosis factor antagonists alone or in combination and risk of lymphoma in patients with inflammatory bowel disease. JAMA. 2017;318(17):1679\u201386.","journal-title":"JAMA"},{"issue":"8","key":"4154_CR48","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1053\/j.gastro.2017.02.004","volume":"152","author":"JS Hyams","year":"2017","unstructured":"Hyams JS, Dubinsky MC, Baldassano RN, Colletti RB, Cucchiara S, Escher J, et al. Infliximab is not associated with increased risk of malignancy or hemophagocytic lymphohistiocytosis in pediatric patients with inflammatory bowel disease. Gastroenterology. 2017;152(8):1901\u2013e19143.","journal-title":"Gastroenterology"},{"issue":"1","key":"4154_CR49","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1007\/s10620-021-06884-9","volume":"67","author":"A Llanos-Chea","year":"2022","unstructured":"Llanos-Chea A, Shapiro JM, Winter RW, Jerger L, Menz T, Gibson M, et al. Lymphoma in pediatric-onset inflammatory bowel disease treated with Infliximab monotherapy: a case series. Dig Dis Sci. 2022;67(1):252\u20138.","journal-title":"Dig Dis Sci"},{"issue":"2","key":"4154_CR50","doi-asserted-by":"publisher","first-page":"354","DOI":"10.14309\/ajg.0000000000002053","volume":"118","author":"MD Egberg","year":"2023","unstructured":"Egberg MD, Zhang X, Smitherman AB, Kappelman MD. Low risk of lymphoma in pediatric patients treated for inflammatory bowel disease. Am J Gastroenterol. 2023;118(2):354\u20139.","journal-title":"Am J Gastroenterol"},{"key":"4154_CR51","doi-asserted-by":"publisher","first-page":"j3951","DOI":"10.1136\/bmj.j3951","volume":"358","author":"O Ol\u00e9n","year":"2017","unstructured":"Ol\u00e9n O, Askling J, Sachs MC, Frumento P, Neovius M, Smedby KE, et al. Childhood onset inflammatory bowel disease and risk of cancer: a Swedish nationwide cohort study 1964\u20132014. BMJ. 2017;358:j3951.","journal-title":"BMJ"},{"issue":"7","key":"4154_CR52","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2023.103332","volume":"22","author":"L De Stefano","year":"2023","unstructured":"De Stefano L, Pallavicini FB, Mauric E, Piccin V, Vismara EM, Montecucco C, et al. Tumor necrosis factor-\u03b1 inhibitor-related autoimmune disorders. Autoimmun Rev. 2023;22(7): 103332.","journal-title":"Autoimmun Rev"},{"issue":"5","key":"4154_CR53","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1111\/pde.14712","volume":"38","author":"BM Cyrenne","year":"2021","unstructured":"Cyrenne BM, Parpia AS, Sibbald C. Paradoxical psoriasis in pediatric patients: A systematic review. Pediatr Dermatol. 2021;38(5):1086\u201393.","journal-title":"Pediatr Dermatol"},{"issue":"1","key":"4154_CR54","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1002\/jpn3.12066","volume":"78","author":"K van Hoeve","year":"2024","unstructured":"van Hoeve K, Thomas D, Hillary T, Hoffman I, Dreesen E. Identifying risk factors of anti-TNF induced skin lesions and other adverse events in paediatric patients with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2024;78(1):95\u2013104.","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"2","key":"4154_CR55","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.cgh.2020.03.018","volume":"19","author":"A Landemaine","year":"2021","unstructured":"Landemaine A, Petitcollin A, Brochard C, Miard C, Dewitte M, Le Balc\u2019h E, et al. Cumulative exposure to infliximab, but not trough concentrations, correlates with rate of infection. Clin Gastroenterol Hepatol. 2021;19(2):288\u2013e2954.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"12","key":"4154_CR56","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1111\/ijd.14072","volume":"57","author":"FJ Melo","year":"2018","unstructured":"Melo FJ, Magina S. Clinical management of anti-TNF-alpha-induced psoriasis or psoriasiform lesions in inflammatory bowel disease patients: a systematic review. Int J Dermatol. 2018;57(12):1521\u201332.","journal-title":"Int J Dermatol"},{"key":"4154_CR57","doi-asserted-by":"publisher","first-page":"847160","DOI":"10.3389\/fimmu.2022.847160","volume":"13","author":"W Xie","year":"2022","unstructured":"Xie W, Xiao S, Huang H, Zhang Z. Incidence of and risk factors for paradoxical psoriasis or psoriasiform lesions in inflammatory bowel disease patients receiving anti-TNF therapy: systematic review with meta-analysis. Front Immunol. 2022;13:847160.","journal-title":"Front Immunol"},{"issue":"4","key":"4154_CR58","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s40272-020-00396-1","volume":"22","author":"C Olbj\u00f8rn","year":"2020","unstructured":"Olbj\u00f8rn C, Rove JB, Jahnsen J. Combination of biological agents in moderate to severe pediatric inflammatory bowel disease: a case series and review of the literature. Paediatr Drugs. 2020;22(4):409\u201316.","journal-title":"Paediatr Drugs"},{"issue":"9","key":"4154_CR59","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1093\/ecco-jcc\/jjac055","volume":"16","author":"MT Dolinger","year":"2022","unstructured":"Dolinger MT, Rolfes P, Spencer E, Stoffels G, Dunkin D, Dubinsky MC. Outcomes of children with inflammatory bowel disease who develop anti-tumour necrosis factor-induced skin reactions. J Crohns Colitis. 2022;16(9):1420\u20137.","journal-title":"J Crohns Colitis"},{"key":"4154_CR60","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2022.109269","volume":"112","author":"C Dai","year":"2022","unstructured":"Dai C, Wang YN, Tian WN, Huang YH, Jiang M. The incidence, clinical characteristics and serological characteristics of anti-tumor necrosis factor-induced lupus in patients with inflammatory bowel disease: a systematic review and meta-analysis. Int Immunopharmacol. 2022;112: 109269.","journal-title":"Int Immunopharmacol"},{"issue":"1","key":"4154_CR61","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.autrev.2013.09.002","volume":"13","author":"E Kaltsonoudis","year":"2014","unstructured":"Kaltsonoudis E, Voulgari PV, Konitsiotis S, Drosos AA. Demyelination and other neurological adverse events after anti-TNF therapy. Autoimmun Rev. 2014;13(1):54\u20138.","journal-title":"Autoimmun Rev"},{"issue":"4","key":"4154_CR62","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1002\/ibd.23011","volume":"19","author":"S Singh","year":"2013","unstructured":"Singh S, Kumar N, Loftus EV Jr, Kane SV. Neurologic complications in patients with inflammatory bowel disease: increasing relevance in the era of biologics. Inflamm Bowel Dis. 2013;19(4):864\u201372.","journal-title":"Inflamm Bowel Dis"},{"issue":"8","key":"4154_CR63","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1001\/jamaneurol.2020.1162","volume":"77","author":"A Kunchok","year":"2020","unstructured":"Kunchok A, Aksamit AJ Jr, Davis JM 3rd, Kantarci OH, Keegan BM, Pittock SJ, et al. Association between tumor necrosis factor inhibitor exposure and inflammatory central nervous system events. JAMA Neurol. 2020;77(8):937\u201346.","journal-title":"JAMA Neurol"},{"key":"4154_CR64","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1111\/bcp.13245","volume":"83","author":"A Puri","year":"2017","unstructured":"Puri A, Niewiarowski A, Arai Y, Nomura H, Baird M, Dalrymple I, et al. Pharmacokinetics, safety, tolerability and immunogenicity of FKB327, a new biosimilar medicine of adalimumab\/humira, in healthy subjects. Br J Clin Pharmacol. 2017;83:1405\u201315.","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"4154_CR65","doi-asserted-by":"publisher","first-page":"65","DOI":"10.5114\/reum.2021.105438","volume":"59","author":"EJ Kucharz","year":"2021","unstructured":"Kucharz EJ, Kotulska-Kucharz A. Tumor necrosis factor alpha inhibitors and demyelinating disease: what is behind it? Reumatologia. 2021;59(2):65\u20137.","journal-title":"Reumatologia"},{"key":"4154_CR66","doi-asserted-by":"publisher","first-page":"513","DOI":"10.3389\/fphar.2020.00513","volume":"11","author":"EM Thillard","year":"2020","unstructured":"Thillard EM, Gautier S, Babykina E, Carton L, Amad A, Bouzill\u00e9 G, et al. Psychiatric adverse events associated with infliximab: a cohort study from the French nationwide discharge abstract database. Front Pharmacol. 2020;11:513.","journal-title":"Front Pharmacol"},{"key":"4154_CR67","doi-asserted-by":"publisher","DOI":"10.2196\/49755","volume":"10","author":"SM Jeon","year":"2024","unstructured":"Jeon SM, Lim H, Cheon HB, Ryu J, Kwon JW. Assessing the labeling information on drugs associated with suicide risk: systematic review. JMIR Public Health Surveill. 2024;10: e49755.","journal-title":"JMIR Public Health Surveill"},{"issue":"6","key":"4154_CR68","doi-asserted-by":"publisher","first-page":"e229","DOI":"10.1097\/pq9.0000000000000229","volume":"4","author":"M Shayowitz","year":"2019","unstructured":"Shayowitz M, Ricardo BM, Grudnikoff AP. Infliximab-induced depression and suicidal behavior in adolescent with crohn\u2019s disease: case report and review of literature. Pediatr Qual Saf. 2019;4(6):e229.","journal-title":"Pediatr Qual Saf"},{"issue":"1","key":"4154_CR69","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1093\/ibd\/izz133","volume":"26","author":"KE Christian","year":"2020","unstructured":"Christian KE, Russman KM, Rajan DP, Barr EA, Cross RK. Gender differences and other factors associated with weight gain following initiation of infliximab: a post hoc analysis of clinical trials. Inflamm Bowel Dis. 2020;26(1):125\u201331.","journal-title":"Inflamm Bowel Dis"},{"issue":"12","key":"4154_CR70","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1080\/00365521.2020.1837929","volume":"55","author":"J Lepp","year":"2020","unstructured":"Lepp J, H\u00f6\u00f6g C, Forsell A, Fyrhake U, L\u00f6rdal M, Almer S. Rapid weight gain in Infliximab treated Crohn\u2019s disease patients is sustained over time: real-life data over 12 months. Scand J Gastroenterol. 2020;55(12):1411\u20138.","journal-title":"Scand J Gastroenterol"},{"issue":"11","key":"4154_CR71","doi-asserted-by":"publisher","first-page":"3110","DOI":"10.1007\/s10620-017-4745-1","volume":"62","author":"L Haas","year":"2017","unstructured":"Haas L, Chevalier R, Major BT, Enders F, Kumar S, Tung J. Biologic agents are associated with excessive weight gain in children with inflammatory bowel disease. Dig Dis Sci. 2017;62(11):3110\u20136.","journal-title":"Dig Dis Sci"},{"issue":"6","key":"4154_CR72","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1016\/j.crohns.2010.05.012","volume":"4","author":"M Torio","year":"2010","unstructured":"Torio M, Ishimura M, Ohga S, Doi T, Utsunomiya R, Ohkubo K, et al. Nephrolithiasis as an extra-intestinal presentation of pediatric inflammatory bowel disease unclassified. J Crohns Colitis. 2010;4(6):674\u20138.","journal-title":"J Crohns Colitis"},{"issue":"9","key":"4154_CR73","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1007\/s00535-022-01903-6","volume":"57","author":"K van Hoeve","year":"2022","unstructured":"van Hoeve K, Hoffman I. Renal manifestations in inflammatory bowel disease: a systematic review. J Gastroenterol. 2022;57(9):619\u201329.","journal-title":"J Gastroenterol"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-025-04154-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-025-04154-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-025-04154-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T15:39:01Z","timestamp":1757345941000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgastroenterol.biomedcentral.com\/articles\/10.1186\/s12876-025-04154-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,7]]},"references-count":73,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4154"],"URL":"https:\/\/doi.org\/10.1186\/s12876-025-04154-w","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,7]]},"assertion":[{"value":"20 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study analyzed secondary data from the FDA Adverse Event Reporting System (FAERS), a publicly accessible and de-identified database. According to U.S. federal regulations (45 CFR 46.104(d)(4)), research involving publicly available, non-identifiable data does not require Institutional Review Board (IRB) approval or individual informed consent. Therefore, no additional ethics approval or participant consent was required for this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"560"}}